An experimental cancer therapy that is being developed by Apogenix GmbH has reportedly induced programmed cell death in different animal models of colon cancer, according to an article in the December issue of Molecular Cancer Therapeutics. ---Subscribe to MedNous to access this article--- Company News Research & University News
